<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03950440</url>
  </required_header>
  <id_info>
    <org_study_id>S61710</org_study_id>
    <nct_id>NCT03950440</nct_id>
  </id_info>
  <brief_title>Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement</brief_title>
  <acronym>IPOD-AV</acronym>
  <official_title>Assessing the Incidence of Postoperative Delirium Following Aortic Valve Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our primary aim in this observational study is to identify the incidence of POD in the first
      five postoperative days by using the 3-minute Diagnostic confusion assessment method (3D-CAM)
      or the derived version for intensive care unit (CAM-ICU) in patients undergoing different
      techniques of aortic valve replacement. Patients are followed 5 days postoperative with the
      3D-CAM or until resolution of POD. Six months postoperatively, a follow-up by phone is
      planned for activity of daily living (ADL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A significant and often underrecognized complication after surgery is postoperative delirium
      (POD) causing increased morbidity and mortality. This is especially true for the older
      cardiac surgical patient, in whom the incidence of POD is up to 70%. Surgical invasiveness
      and herewith related inflammation, a cholinergic load of medications, postoperative pain or
      use of opioids are examples of precipitating factors that can be altered to reduce the
      incidence of POD. Transaortic valve replacement (TAVR) is a revolutionary technique that has
      led to a dramatic decrease in surgical invasiveness and improved outcomes in high-risk
      surgical patients. However, only a few studies evaluated neurocognitive outcome after
      surgical aortic valve replacement (SAVR) compared to TAVR, suggesting a reduced incidence of
      POD with TAVR compared to SAVR. In contrast, other studies found almost no difference in POD
      in the aforementioned patient groups. Hence, it remains still unclear which technique best to
      use in patients at high risk for POD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of postoperative delirium</measure>
    <time_frame>During the first five postoperative days or until discharge, in case of POD followup until resolution of POD or discharge.</time_frame>
    <description>Using the 3-minute Diagnostic confusion assessment method (3D-CAM) or the derived version for intensive care unit (CAM-ICU)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset postoperative delirium</measure>
    <time_frame>During the first five postoperative days or discharge</time_frame>
    <description>Moment of onset of POD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of POD</measure>
    <time_frame>If POD develops during the first 5 postoperative days, patient will be followed until POD has resolved or until discharge</time_frame>
    <description>Duration of delirium in days using the 3D-CAM or ICU-CAM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of POD</measure>
    <time_frame>If POD develops during the first 5 postoperative days, patient will be followed until POD has resolved or until discharge</time_frame>
    <description>assessed with the delirium severity measure-based CAM (CAM-S Long)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of subsyndromal delirium</measure>
    <time_frame>During the first five postoperative days or discharge</time_frame>
    <description>assessed with the delirium severity measure-based CAM (CAM-S Long)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early safety according to VARC-2</measure>
    <time_frame>30 days</time_frame>
    <description>Early safety (at 30 days) defined by the Valve Academic Research Consortium (VARC)-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy according to VARC-2</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical efficacy (at 6 months) as defined by VARC-2</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intensive care unit (ICU) length of stay</measure>
    <time_frame>30 days</time_frame>
    <description>Intensive care unit (ICU) length of stay</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>30 days</time_frame>
    <description>Amount of days hospitalized in the primary center</description>
  </other_outcome>
  <other_outcome>
    <measure>Discharge destination</measure>
    <time_frame>30 days</time_frame>
    <description>Discharge destination defined as: home, nursing home, revalidation unit or other hospital.</description>
  </other_outcome>
  <other_outcome>
    <measure>6-months interview</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of different questionnaires: self-administered instrumental activities of daily living, 5 dimensional quality of life (EQ-5D-5L), visual analoge scale for quality of life (EQ-VAS) and cognitive failure questionnaire.</description>
  </other_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Postoperative Delirium</condition>
  <condition>Aortic Valve Stenosis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      presence of neural injury markers
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient presenting for the indicated surgery in a tertiary university hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled to undergo elective

               -  TAVI

               -  SAVR (with or without coronary artery bypass grafting (CABG) or pulmonary vein
                  isolation (PVI))

          -  Patient able to read and understand the research materials

        Exclusion Criteria:

          -  Inability to give informed consent

          -  Presence of delirium at baseline as screened with the 3-minute Diagnostic Confusion
             Assessment Method (3D-CAM)

          -  Combined surgical procedures (e.g. mitral valve surgery, aortic surgery or other)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danny Hoogma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danny Hoogma, MD</last_name>
    <phone>003216344270</phone>
    <email>danny.hoogma@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christel Huygens</last_name>
    <phone>003216344270</phone>
    <email>christel.huygens@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Hoogma, MD</last_name>
      <phone>003216344270</phone>
      <email>danny.hoogma@uzleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>May 10, 2019</last_update_submitted>
  <last_update_submitted_qc>May 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>dr. Danny Hoogma</investigator_full_name>
    <investigator_title>Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>Transaortic valve replacement</keyword>
  <keyword>Surgical aortic valve replacement</keyword>
  <keyword>TAVR</keyword>
  <keyword>SAVR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT03950440/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

